Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up

Executive Summary

FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing

You may also be interested in...



Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees

FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003

Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees

FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003

CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.

The House Energy & Commerce Committee investigation of the Erbitux review could re-energize proposals to combine FDA's drugs and biologics centers

Related Content

UsernamePublicRestriction

Register

PS040078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel